We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Automated Approach Predicts Alzheimer's Disease Risk

By LabMedica International staff writers
Posted on 08 Jul 2019
Print article
Image: The cobas e 601 module for immunoassay tests (Photo courtesy of Roche Diagnostics).
Image: The cobas e 601 module for immunoassay tests (Photo courtesy of Roche Diagnostics).
An automated immunodiagnostic test predicts risk of developing Alzheimer's disease by measuring the level of beta-amyloid (Abeta) in the blood, which accurately reflects the accumulation of this protein in the brain.

Investigators at Lund University (Sweden) have been searching for accurate blood-based biomarkers for Alzheimer disease (AD), which might improve diagnostic accuracy in primary care settings, increase referrals to memory clinics, and aid in screenings for AD trials.

Towards this end, the investigators analyzed plasma and cerebral spinal fluid (CSF) Abeta42, Abeta40, total tau (tau), and phosphorylated tau (P-tau; only in CSF) using Elecsys immunoassays on a Roche Diagnostics cobas e 601 autoanalyzer.

The cobas e 601 module is a fully automated analyzer that uses a patented electrochemiluminescence (ECL) technology for immunoassay analysis. It was designed for both quantitative and qualitative in vitro assay determinations for a broad range of applications (including anemia; bone, cardiac and tumor markers; critical care; fertility hormones; maternal care; and infectious diseases).

For the current study, the investigators used Elecsys immunoassays to analyze blood samples collected from 842 people in Sweden (The Swedish BioFINDER study) and 237 people in Germany. The cerebrospinal fluid (CSF) Abeta42/Abeta40 ratio was used as the reference standard for brain Abeta status.

The mean age of the 842 participants in the first cohort was 72 years, with a range of 59 to 88 years, and 446 (52.5%) were female. For the 237 subjects in the second cohort, mean age was 66 years with a range of 23 to 85 years, and 120 (50.6%) were female. In the first cohort, plasma Abeta42 and Abeta40 predicted Abeta status with an area under the receiver operating characteristic curve (AUC) of 0.80. When adding APOE, the AUC increased significantly to 0.85.

"Previous studies on methods using blood tests did not show particularly good results; it was only possible to see small differences between Alzheimer's patients and healthy elderly people. Only a year or so ago, researchers found methods using blood sample analysis that showed greater accuracy in detecting the presence of Alzheimer's disease. The difficulty so far is that they currently require advanced technology and are not available for use in today's clinical procedures," said first author Dr. Sebastian Palmqvist, associate professor for clinical memory research at Lund University. "The next step to confirm this simple method to reveal beta-amyloid through blood sample analysis is to test it in a larger population where the presence of underlying Alzheimer's is lower. We also need to test the technique in clinical settings, which we will do fairly soon in a major primary care study in Sweden. We hope that this will validate our results."

The study was published in the June 24, 2019, online edition of the journal JAMA Neurology.

Related Links:
Lund University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.